Brief: Shenzhen Hepalink Pharmaceutical Group Posts HY Profit Attributable Of RMB338.2 Mln
26/08/2021 14:34
Aug 26 (Reuters) - Shenzhen Hepalink Pharmaceutical Group Co
Ltd 002399.SZ :
* HY PROFIT ATTRIBUTABLE RMB338.2 MILLION, DECREASE OF 41.8%
* HY REVENUE RMB3,111.2 MILLION, INCREASE OF ABOUT 18.0%
Further company coverage: 002399.SZ
(Reuters.Briefs@thomsonreuters.com)
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA